CoChat

Proof-of-Concept Workflow for Establishing Reference Intervals of Human Urine Proteome for Monitoring Physiological and Pathological Changes

Open access
Leng, Wenchuan, Ni, Xiaotian, Sun, Changqing, Lu, Tianyuan, Malovannaya, Anna, Jung, Sung Yun, Huang, Yin, Qiu, Yang, Sun, Guannan, Holt, Matthew V., Ding, Chen, Sun, Wei, Men, Xuebo, Shi, Tieliu, Zhu, Weimin, Wang, Yi, He, Fuchu, Zhen, Bei, Wang, Guangshun, Qin, Jun · 2017 · EBioMedicine
Cited by 44

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Urine as a true non-invasive sampling source holds great potential for biomarker discovery. While approximately 2000 proteins can be detected by mass spectrometry in urine from healthy people, the amount of these proteins vary considerably. A systematic evaluation of a large number of samples is needed to determine the range of the variations. Current biomarker studies often measure limited number of urine samples in the discovery phase, which makes it difficult to determine whether proteins differentially expressed between control and disease groups represent actual difference, or are just physiological variations among the individuals, leads to failures in the validation phase with the increased sample numbers. Here, we report a streamlined workflow with capacity of measuring 8 urine proteomes per day at the coverage of >1500 proteins. With this workflow, we evaluated variations in 497 urine proteomes from 167 healthy donors, establishing reference intervals (RIs) that covered urine protein variations. We demonstrated that RIs could be used to monitor physiological changes by detecting transient outlier proteins. Furthermore, we provided a RIs-based algorithm for biomarker discovery and validation to screen for diseases such as cancer. This study provided a proof-of-principle workflow for the use of urine proteome for health monitoring and disease screening.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ebiom.2017.03.028

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 42

  1. Adachi, 2006, The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins, Genome Biol., 7, R80, 10.1186/gb-2006-7-9-r80 · DOI · Paper page
  2. Anderson, 2010, The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum, Clin. Chem., 56, 177, 10.1373/clinchem.2009.126706 · DOI · Paper page
  3. Beretov, 2015, Proteomic analysis of urine to identify breast cancer biomarker candidates using a label-free LC-MS/MS approach, PLoS One, 10, 10.1371/journal.pone.0141876 · DOI
  4. Coon, 2008, CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics, Proteomics Clin. Appl., 2, 964, 10.1002/prca.200800024 · DOI · Paper page
  5. Court, 2015, Urine sample preparation and fractionation for global proteome profiling by LC-MS, Methods Mol. Biol., 1243, 175, 10.1007/978-1-4939-1872-0_10 · doi:10.1007/978-1-4939-1872-0_10
  6. Decramer, 2008, Urine in clinical proteomics, Mol. Cell. Proteomics, 7, 1850, 10.1074/mcp.R800001-MCP200 · DOI · Paper page
  7. Diamond, 2013, The broad-spectrum antiviral functions of IFIT and IFITM proteins, Nat. Rev. Immunol., 13, 46, 10.1038/nri3344 · DOI · Paper page
  8. Draghici, 2003, Global functional profiling of gene expression, Genomics, 81, 98
  9. Fuzery, 2013, Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges, Clin. Proteomics, 10, 13, 10.1186/1559-0275-10-13 · DOI · Paper page
  10. Gao, 2013, Urine-an untapped goldmine for biomarker discovery?, Sci. China Life Sci., 56, 1145, 10.1007/s11427-013-4574-1 · DOI · Paper page
  11. Goodison, 2009, Urinary proteomic profiling for diagnostic bladder cancer biomarkers, Expert Rev Proteomics, 6, 507, 10.1586/epr.09.70 · DOI
  12. Haller, 2006, The interferon response circuit: induction and suppression by pathogenic viruses, Virology, 344, 119, 10.1016/j.virol.2005.09.024 · DOI · Paper page
  13. Hammarstrom, 1999, The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues, Semin. Cancer Biol., 9, 67, 10.1006/scbi.1998.0119 · DOI · Paper page
  14. Hamosh, 2005, Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders, Nucleic Acids Res., 33, D514, 10.1093/nar/gki033 · DOI · Paper page
  15. Kentsis, 2009, Urine proteomics for profiling of human disease using high accuracy mass spectrometry, Proteomics Clin. Appl., 3, 1052, 10.1002/prca.200900008 · DOI
  16. Khristenko, 2016, Longitudinal urinary protein variability in participants of the space flight simulation program, J. Proteome Res., 15, 114, 10.1021/acs.jproteome.5b00594 · DOI
  17. Lv, 2012, Altered expression levels of IDH2 are involved in the development of colon cancer, Exp. Ther. Med., 4, 801, 10.3892/etm.2012.676 · DOI
  18. Malovannaya, 2010, Streamlined analysis schema for high-throughput identification of endogenous protein complexes, Proc. Natl. Acad. Sci. U. S. A., 107, 2431, 10.1073/pnas.0912599106 · DOI · Paper page
  19. Marimuthu, 2011, A comprehensive map of the human urinary proteome, J. Proteome Res., 10, 2734, 10.1021/pr2003038 · DOI · Paper page
  20. Mischak, 2010, Recommendations for biomarker identification and qualification in clinical proteomics, Sci. Transl. Med., 2, 10.1126/scitranslmed.3001249 · DOI · Paper page
  21. Nagaraj, 2011, Quantitative analysis of the intra- and inter-individual variability of the normal urinary proteome, J. Proteome Res., 10, 637, 10.1021/pr100835s · DOI · Paper page
  22. Overbye, 2015, Identification of prostate cancer biomarkers in urinary exosomes, Oncotarget, 6, 30357, 10.18632/oncotarget.4851 · DOI · Paper page
  23. Pavlou, 2013, The long journey of cancer biomarkers from the bench to the clinic, Clin. Chem., 59, 147, 10.1373/clinchem.2012.184614 · DOI · Paper page
  24. Pisitkun, 2006, Discovery of urinary biomarkers, Mol. Cell. Proteomics, 5, 1760, 10.1074/mcp.R600004-MCP200 · DOI · Paper page
  25. Pisitkun, 2004, Identification and proteomic profiling of exosomes in human urine, Proc. Natl. Acad. Sci. U. S. A., 101, 13368, 10.1073/pnas.0403453101 · DOI · Paper page
  26. Raimondo, 2013, Differential protein profiling of renal cell carcinoma urinary exosomes, Mol. BioSyst., 9, 1220, 10.1039/c3mb25582d · DOI · Paper page
  27. Rodriguez-Suarez, 2014, Urine as a source for clinical proteome analysis: from discovery to clinical application, Biochim. Biophys. Acta, 1844, 884, 10.1016/j.bbapap.2013.06.016 · DOI
  28. Santucci, 2015, From hundreds to thousands: widening the normal human Urinome (1), J. Proteome, 112, 53, 10.1016/j.jprot.2014.07.021 · DOI
  29. Shao, 2015, Urinary protein biomarker database: a useful tool for biomarker discovery, Adv. Exp. Med. Biol., 845, 195, 10.1007/978-94-017-9523-4_19 · DOI
  30. Shao, 2011, A tool for biomarker discovery in the urinary proteome: a manually curated human and animal urine protein biomarker database, Mol. Cell. Proteomics, 10, 010975
  31. Shao, 2011, Applications of urinary proteomics in biomarker discovery, Sci. China Life Sci., 54, 409, 10.1007/s11427-011-4162-1 · DOI
  32. Stetson, 2006, Type I interferons in host defense, Immunity, 25, 373, 10.1016/j.immuni.2006.08.007 · DOI · Paper page
  33. Sun, 2009, Dynamic urinary proteomic analysis reveals stable proteins to be potential biomarkers, Proteomics Clin. Appl., 3, 370, 10.1002/prca.200800061 · DOI
  34. Sun, 2005, Human urine proteome analysis by three separation approaches, Proteomics, 5, 4994, 10.1002/pmic.200401334 · DOI
  35. Thompson, 2004, Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter, N. Engl. J. Med., 350, 2239, 10.1056/NEJMoa031918 · DOI · Paper page
  36. Uhlen, 2015, Proteomics. Tissue-based map of the human proteome, Science, 347, 1260419, 10.1126/science.1260419 · DOI · Paper page
  37. Wang, 2006, Concanavalin A-captured glycoproteins in healthy human urine, Mol. Cell. Proteomics, 5, 560, 10.1074/mcp.D500013-MCP200 · DOI
  38. Wang, 2017, Exosomal proteins as prostate cancer biomarkers in urine: from mass spectrometry discovery to immunoassay-based validation, Eur. J. Pharm. Sci., 98, 80, 10.1016/j.ejps.2016.09.023 · DOI
  39. Wu, 2015, Physiological conditions can be reflected in human urine proteome and metabolome, Expert. Rev. Proteom., 12, 623, 10.1586/14789450.2015.1094380 · DOI · Paper page
  40. Yamamoto, 2008, Towards standard protocols and guidelines for urine proteomics: a report on the Human Kidney and Urine Proteome Project (HKUPP) symposium and workshop, 6 October 2007, Seoul, Korea and 1 November 2007, San Francisco, CA, USA, Proteomics, 8, 2156, 10.1002/pmic.200800138 · doi:10.1002/pmic.200800138
  41. Yu, 2014, Urine sample preparation in 96-well filter plates for quantitative clinical proteomics, Anal. Chem., 86, 5470, 10.1021/ac5008317 · DOI
  42. Zhang, 2007, MAPU: Max-Planck Unified database of organellar, cellular, tissue and body fluid proteomes, Nucleic Acids Res., 35, D771, 10.1093/nar/gkl784 · DOI

Cited by

Metadata

Authors
Leng, W., Ni, X., Sun, C., Lu, T., Malovannaya, A., Jung, S. Y., Huang, Y., Qiu, Y., Sun, G., Holt, M. V., Ding, C., Sun, W., Men, X., Shi, T., Zhu, W., Wang, Y., He, F., Zhen, B., Wang, G., & Qin, J.
Venue
EBioMedicine
Publisher
Elsevier BV
Published
2017-04
Volume
18
Pages
300-310
ISSN
2352-3964 (ISSN-L)
OpenAlex
W2601317354
Cited by
44
References
9
FWCI
2.18
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.